Hereditary site-specific ovarian cancer syndrome

Advocacy intelligence hub — real-time data for patient organizations

View full disease page →Search clinical trials →
Download CSV

At a Glance

Live from database

Regulatory Watchboard

No FDA or trial events recorded yet for Hereditary site-specific ovarian cancer syndrome.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

1

Total programs

1

Open now

Patient Assistance Programs1

Avmapki Fakzynja Co-Pack

Verastem, Inc.

OpenContact for details

View all support programs on disease page →

Approved Treatments

1 FDA-approved

Avmapki Fakzynja Co-Pack

(avutometinib; defactinib)Orphan drugaccelerated

Verastem, Inc.

12.1 Mechanism of Action Avutometinib Avutometinib is a MEK1 inhibitor. Avutometinib induces the formation of inactive RAF/MEK complexes and prevents ...

FDA label ↗

View full treatment details on disease page →

Clinical Trial Landscape

No active clinical trials currently recruiting for Hereditary site-specific ovarian cancer syndrome.
Search all trials →
Search clinical trials for Hereditary site-specific ovarian cancer syndrome

Recent News & Research

No recent news articles indexed yet for Hereditary site-specific ovarian cancer syndrome.
Search PubMed for Hereditary site-specific ovarian cancer syndrome

Browse all Hereditary site-specific ovarian cancer syndrome news →

Specialist Network

Top 6 by expertise

View all Hereditary site-specific ovarian cancer syndrome specialists →

Quick Actions